Another study suggested that FGF21 inhibits the progression of NASH to hepatocellular carcinoma through inhibition of Toll-like receptors and interleukin-17 signaling in hepatocytes. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.